A Randomized, Single Intravenous Dose, Parallel Phase I Clinical Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX05 Vs. Erbitux ® (Cetuximab) in Healthy Adult Male Chinese Subjects

Conditions: EGFR Overexpression Interventions: Drug: recombinant anti-EGFR human/murine chimeric monoclonal antibody injection Sponsors: Shanghai Henlius Biotech Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials